1/17/2019 6:59:29 AM
Wedbush Is Increasing Five Prime Therapeutics (FPRX) FY18 Rev. Estimate To 53.6 M From 53.3 M
1/17/2019 6:59:19 AM
Wedbush Is Increasing Five Prime Therapeutics (FPRX) Q4 18 Rev. Estimate To 7.8 M From 7.5 M
1/17/2019 6:58:59 AM
Wedbush Is Raising Five Prime Therapeutics (FPRX) FY19 Estimate To -3.78 From -5.14
1/17/2019 6:58:47 AM
Wedbush Is Increasing Five Prime Therapeutics (FPRX) Q4 19 Estimate To -0.90 From -1.33
1/17/2019 6:58:35 AM
Wedbush Is Raising Five Prime Therapeutics (FPRX) Q3 19 Estimate To -0.89 From -1.30
1/17/2019 6:58:23 AM
Wedbush Is Raising Five Prime Therapeutics (FPRX) Q2 19 Estimate To -0.94 From -1.29
1/17/2019 6:58:10 AM
Wedbush Is Raising Five Prime Therapeutics (FPRX) Q1 19 Estimate To -1.05 From -1.23
1/17/2019 6:57:53 AM
Wedbush Is Raising Five Prime Therapeutics (FPRX) FY18 Estimate To -4.34 From -4.41
1/17/2019 6:57:41 AM
Wedbush Is Increasing Five Prime Therapeutics (FPRX) Q4 18 Estimate To -1.35 From -1.41
1/17/2019 6:56:52 AM
Wedbush Raises Five Prime Therapeutics (FPRX) To Outperform From Neutral With $16 Price Target
11/8/2018 8:26:47 AM
Wedbush Is Cutting Five Prime Therapeutics (FPRX) FY18 Rev. Estimate To 53.3 M From 55.1 M
11/8/2018 8:26:23 AM
Wedbush Is Lowering Five Prime Therapeutics (FPRX) FY18 Estimate To -5.14 From -4.19
11/8/2018 8:26:02 AM
Wedbush Is Cutting Five Prime Therapeutics (FPRX) FY18 Estimate To -4.41 From -3.95
11/8/2018 8:25:48 AM
Wedbush Is Cutting Five Prime Therapeutics (FPRX) Q4 18 Estimate To -1.41 From -1.19
11/5/2018 10:43:26 AM
Five Prime Therapeutics Appoints David Smith As CFO
10/1/2018 8:12:58 AM
Five Prime Therapeutics, Zai Lab Dose First Patient In Phase 3, Global Registrational Trial Of Bemarituzumab
9/10/2018 9:06:50 AM
Five Prime Completes Phase 1 Safety Lead-In And Initiates Phase 3, Global Registrational Trial Of Bemarituzumab
8/10/2018 7:33:25 AM
Wedbush Is Increasing Five Prime Therapeutics (FPRX) FY18 Rev. Estimate To 55.1 M From 32.5 M